V
The startup develops live-attenuated vaccines targeting bronchiolitis and pneumonia, specifically against human metapneumovirus and human respiratory virus. By focusing on these critical respiratory diseases, the company aims to enhance treatment options and improve patient outcomes in the healthcare sector.
Updated 3 months ago
Funding
$2.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops live-attenuated vaccines targeting bronchiolitis and pneumonia, specifically against human metapneumovirus and human respiratory virus. By focusing on these critical respiratory diseases, the company aims to enhance treatment options and improve patient outcomes in the healthcare sector.